Andrew Robbins is the CEO and President of Cogent Biosciences, a company he joined in October 2020. He has a strong background in the pharmaceutical industry, particularly in oncology and hematology. Andrew holds an MBA from the Kellogg School of...

Andrew Robbins is the CEO and President of Cogent Biosciences, a company he joined in October 2020. He has a strong background in the pharmaceutical industry, particularly in oncology and hematology. Andrew holds an MBA from the Kellogg School of Management at Northwestern, which complements his practical experience. Previously, he was the Chief Operating Officer at Array BioPharma until its acquisition by Pfizer. Under his leadership, Cogent continues to focus on developing therapies for genetically defined diseases. In 2023, his total compensation was around $1 million. Notably, when Andrew joined the company, he was awarded a significant option inducement grant, demonstrating the trust placed in him to drive the company's growth. He currently holds a significant number of shares in Cogent, reflecting his commitment to the company's future. Additionally, he serves on the board of other biotech firms, where he shares his expertise.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Cogent Biosciences, Inc. CEOs

C

Andrew Robbins

CEO of Cogent Biosciences, Inc.

Education

MBA from the Kellogg School of Management, Northwestern University and a bachelor’s degree from Swarthmore College

Sector of Economy

Healthcare

CEO of Cogent Biosciences, Inc. for

4 years 8 months (Oct 2020 - Present)

Previous Experience

Chief Operating Officer at Array BioPharma Inc.

Rivals

Competitors/colleagues of Andrew Robbins

Holdings

See how much did Andrew Robbins make over time.

As of March 31, 2023, Andrew Robbins holds approximately 1.9 million shares in Cogent Biosciences, which positions him as a considerable shareholder in the company. His stake represents about 2.6% of the total shares outstanding, reflecting his deep involvement and...

As of March 31, 2023, Andrew Robbins holds approximately 1.9 million shares in Cogent Biosciences, which positions him as a considerable shareholder in the company. His stake represents about 2.6% of the total shares outstanding, reflecting his deep involvement and investment in the company's mission. In previous years, his holdings experienced fluctuations in response to the company's performance and stock growth. When Robbins first joined in October 2020, he received an option grant under the Inducement Plan, providing him with a platform to significantly increase his wealth tied to the company’s success over time. His commitment is clear, as his wealth is closely linked to the performance of Cogent, aligning his interests with those of shareholders.

Loading...

Insider Trading

See recent insider trades of Andrew Robbins.

No insider trades found for this CEO.

Compensation History

See how much did Andrew Robbins make over time.

In 2023, Andrew Robbins's total compensation was approximately $1,002,957, which included a base salary of $656,098 and a bonus of $393,659 that was tied to performance metrics. He did not report any stock grants or stock options as vested that year, which highlights that his pay is primarily based on cash incentives rather than long-term equity at this point. This compensation structure is designed to keep the focus on achieving company goals and value creation. In 2022, his total compensation reached approximately $4.4 million, reflecting a significantly higher value attributed to his compensation packages during that time. Over the years, his compensation has fluctuated, but it consistently emphasizes aligning rewards with performance metrics.

Year

2023

Total Compensation

$1.06M

Salary

$656.10K

Board Justification

The compensation philosophy targets the 50th percentile of peer group compensation, aligning with company performance and retention strategies.

Bonus

$393.66K

Board Justification

Cash bonuses for the 2023 performance year were funded at 125% of target based on achievement of nearly all target and stretch goals in 2023.

Other

$13.20K

Board Justification

Represents the value of 401(k) contributions made by the Company.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

Cash bonuses are based on company performance against established goals.

Other Cogent Biosciences, Inc. CEOs

Here are other CEOs of Cogent Biosciences, Inc.

Charles Wilson, Ph.D.

Ex-CEO of Cogent Biosciences, Inc.

July 2020 - October 2020